While IL-6Rα mAbs, tocilizumab and sarilumab, have made recent headway in clinical studies for breast cancer, drug repurposing remains an attractive therapeutic strategy to minimize the expensive, time-consuming drug development process (210). Here, IL6R is linked to breast carcinoma.